C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
Ruxolitinib and survival improvement in patients with myelofibrosis
Francesco Passamonti,Alessandro M. Vannucchi,Francisco Cervantes,Claire N. Harrison,E. Morra,Hagop M. Kantarjian,Srdan Verstovsek +6 more
TL;DR: In this analysis, the survival improvement with ruxolitinib in patients with primary myelofibrosis (PMF) is discussed and the selection bias is reduced by including in the untreated cohort only Dynamic International Prognostic Scoring System (DIPSS) patients who matched as best as possible the inclusion criteria in the COMFORT-2 study.
Journal ArticleDOI
MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients
John Mascarenhas,Claire N. Harrison,Katarina Luptakova,Jing Wang,Gozde Colak,James Shao,Suresh Bobba,Patrick Trojer,Jeffrey S. Humphrey,Srdan Verstovsek +9 more
TL;DR: CPI-0610, a potential disease-modifying therapeutic agent with a novel MoA may improve the outcome in JAKi treatment-naive patients with primary MF, post-polycythemia-vera MF, or post-essential-thrombocythemia MF.
Circulating YKL-40 in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV) treated with the Novel Histone Deacetylase Inhibitor Vorinostat
Christen Lykkegaard Andersen,Mads Emil Bjørn,Mary Frances McMullin,Elisabeth Ejerblad,Sonja Zweegman,Claire N. Harrison,Savio Fernandes,David Bareford,Steven Knapper,J. Samuelsson,Eva Löfvenberg,Olle Linder,Bjorn Andreasson,Erik Ahlstrand,Morten K. Jensen,Ole Weis Bjerrum,Hanne Vestergaard,Herdis Larsen,Tobias Wirenfeldt Klausen,Torben Mourits-Andersen,Jakob Werner Hansen,Vibe Skov,Mads Thomassen,Kirsten Grønbæk,Hans Carl Hasselbalch +24 more
TL;DR: YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms and is investigated before and after treatment with vorinostat in polycythemia vera and essential thrombocythemia patients.
Journal ArticleDOI
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial
Ruben A. Mesa,Ronald Hoffman,Heidi E. Kosiorek,Josef T. Prchal,Claire N. Harrison,Mary Frances McMullin,Abdulraheem Yacoub,Alessandro Rambaldi,Dmitriy Berenzon,Alessandro M. Vannucchi,Joanne Ewing,Casey O'Connell,Jean-Jacques Kiladjian,Adam J. Mead,Elliott F. Winton,David S. Leibowitz,Valerio De Stefano,Murat O. Arcasoy,Craig M. Kessler,Rosalind Catchatorian,Damiano Rondelli,Richard T. Silver,Ellen K. Ritchie,Arnon Nagler,Marina Kremyanskaya,Richard F. Schlenk,Rona Singer Weinberg,Mohamed E. Salama,Gianni Tognoni,Giuseppe Prosperini,Alessandra Di Lelio,Eliseo Serone,Lorenzo Marfisi,Alicia Orellana,Tiziano Barbui,Amylou C. Dueck,John Mascarenhas +36 more
TL;DR: This trial randomly assigned 168 therapy-naive high risk ET/PV pts to response adjusted pegylated interferon alpha 2a (PEG) or HU and found that on HU, pts experienced worsening QoL (physical, cognitive functioning, HRQoL) and some persistent or transient worsened symptoms.
Journal ArticleDOI
Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients
Srdan Verstovsek,Miklos Egyed,Ewa Lech-Marańda,Tomasz Sacha,Viviane Dubruille,Stephen T. Oh,Doroteya K. Todorieva-Todorova,Francesco Passamonti,Blanca Xicoy,Bjorn Andreasson,Daniel El Fassi,Claire N. Harrison,Donal P. McLornan,Mary Frances McMullin,Christof Scheid,Marianne Tang Severinsen,Mark Kowalski,Gregg Smith,Ruben A. Mesa +18 more
TL;DR: Momelotinib is a potent JAK1, JAK2 and ACVR1 inhibitor with clinical activity against the three hallmark features of myelofibrosis, demonstrating robust and consistent survival outcomes for patients who commenced JAKi therapy with MMB and those dosed initially with RUX/BAT followed by MMB.